Clinical trial readout dates for Denali Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 1/2 DNL593 Frontotemporal Dementia · NCT05262023 | December 2026 Ongoing |
| Phase 2 BIIB122 225 mg Parkinson Disease · NCT06602193 | March 2027 Ongoing |
| Phase 2/3 tividenofusp alfa Mucopolysaccharidosis II · NCT06075537 | June 2027 Enrolling |
| Phase 2/3 tividenofusp alfa Mucopolysaccharidosis II · NCT05371613 | December 2027 Ongoing |
| Phase 1/2 tividenofusp alfa Mucopolysaccharidosis II · NCT04251026 | February 2031 Ongoing |
| Phase 1/2 DNL126 Mucopolysaccharidosis Type IIIA · NCT06181136 | July 2032 Recruiting |
Denali Therapeutics Inc. reported $1.01B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). It reported net income of $70M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |